Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721734 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00721734 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 50 participants.
The verdict
NCT00721734, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721734
The ClinicalTrials.gov registry entry for NCT00721734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT00721734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721734 about?
NCT00721734 is a clinical study titled "Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function". The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
What is the current status of trial NCT00721734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00721734?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT00721734?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.